Share this video  

ESMO 2018 | Osimertinib for treating non-small cell lung cancer

In this video, clinical data from two clinical trials are discussed for the use of osimertinib, a third generation inhibitor of epidermal growth factor receptor (EGFR), in EGFR-mutated non-small cell lung cancer (NSCLC). James Spicer, FCRP, PhD, MRCP, MBBS, of the Guy’s and St Thomas’ NHS Foundation Trust, London, UK, speaks from the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, comparing the clinical results from the two trials while answering some of the key questions surrounding resistance mechanisms against osimertinib.